Iconovo and Lonza Enter LOI for Strategic Partnership
Iconovo and Lonza have signed a Letter of Intent to establish a long-term collaboration focused on inhalable biologics. This agreement aims to secure their respective positions in the biological medicines sector. Jan Vertommen, VP at Lonza, confirmed the company's interest in inhalable therapies and the intent to expand cooperation with Iconovo.
Senzime Secures SEK 50 Million Credit Facility
Senzime has signed an agreement for a credit facility totaling SEK 50 million. This financing supports the company's continued commercialization and general corporate purposes, securing liquidity for upcoming operational needs. The agreement provides financial resources to back the company's ongoing sales expansion.
Novo Nordisk Receives EC Approval
The European Commission has authorized a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide) for adults with obesity. This approval provides a higher dosage option for patients requiring further weight loss intervention. The decision allows the company to expand its obesity treatment offerings in Europe.
Biostock